The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Epigenetic Mechanisms Regulating HIV CNS Latency and Neuropathogenesis Using Novel Single Cell Technologies (R01, R21 Clinical Trial Not Allowed)
The purpose of this Funding Opportunity Announcement (FOA) is to support studies on the epigenetic mechanisms regulating HIV Central Nervous System (CNS) latency and/or neuropathogenesis using in-vitro (macrophages, microglia and astrocytes, organoids), ex-vivo (post-mortem tissues) and in-vivo systems (animal models). Strategies to target epigenetic pathways for achieving sustained HIV remission and treatment of HIV associated-CNS dysfunction are encouraged. The use novel single cell technologies are also strongly encouraged but is not a requirement. Basic and translational research in domestic and international settings are of interest. Multidisciplinary research teams and collaborations are encouraged but not required. High risk/high payoff projects that lack preliminary data may be most appropriate for the companion R21 FOA, RFA-MH-22-281 while applicants with preliminary data may wish to apply using the R01 mechanism.
Letter of Intent Due Date(s): 30 days prior to the application due date.
AIDS Due Date: Dec. 5, 2022
RFA-MH-22-280 Expiration Date December 06, 2022